中东和非洲子宫癌治疗和诊断市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

中东和非洲子宫癌治疗和诊断市场按癌症类型(子宫内膜腺癌、腺鳞癌、乳头状浆液性癌、子宫肉瘤)、产品和地理进行细分。

市场快照

Market Snapshot1
Study Period: 2018 - 2026
Base Year: 2021
CAGR: 5.7 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

在预测期内,中东和非洲子宫癌治疗和诊断市场预计将以 5.7% 的复合年增长率增长。推动该市场增长的关键因素是对子宫疾病及其可用疗法的认识提高、药物开发中医疗保健支出的增加以及随后的技术进步。

在南非,南非癌症协会 (CANSA) 是一个为该国癌症患者提供综合服务的组织。其使命包括提供有关降低癌症风险的研究,对公众进行有关症状、筛查和降低风险的教育,并为所有受癌症影响的人提供护理和支持。此外,南非卫生部实施了改善妇女健康的计划,所有这些计划都有望在不久的将来增加早期诊断程序。

根据国家临床试验 (NCT) 登记处,截至 2020 年 6 月 18 日,沙特阿拉伯“ASPIRE”临床试验正处于 II 期开发阶段,用于通过立体定向消融放射 (SABR/SBRT) 疗法治疗子宫内膜癌。在不久的将来,如果试验显示出积极的结果,那么它将推动市场,因为预计未来几年会出现新的治疗方法。

因此,这些举措和研究工作有望在未来推动该地区的市场。

Scope of the report

As per the scope of the report, uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. The market is segmented by type of cancer, therapeutics, diagnostics and geography.

By Cancer Type
Endometrial Adenocarcinoma
Adenosquamous Carcinoma
Papillary Serous Carcinoma
Uterine Sarcoma
By Product
Therapeutics
Surgery
Immunotherapy
Radiation Therapy
Chemotherapy
Others Therapeutics
Diagnostics
Biopsy
Pelvic Ultrasound
Hysteroscopy
Dilation and Curettage
CT Scan
Geography
Middle-East & Africa
GCC
South Africa
Rest of Middle-East & Africa

Report scope can be customized per your requirements. Click here.

主要市场趋势

子宫内膜腺癌部分预计将在预测期内见证最高增长

预计子宫内膜腺癌日益增加的负担将推动该领域的子宫癌治疗和诊断市场。

女性肥胖的增加被认为是导致子宫内膜癌发病率增加的主要因素。随着该病发病率的增加和对该病认识的提高,相信该细分市场将在未来出现快速增长。

此外,子宫内膜癌通常在相对较早的阶段产生症状,因此该疾病通常被早期诊断,这一因素推动了未来几年的市场,因为早期诊断子宫内膜癌的诊断程序将增加。

根据国家临床试验 (NCT) 登记处,截至 2020 年 6 月 18 日,默克夏普和多姆公司正在以色列、南非和其他国家进行子宫内膜的 II 期临床试验 ((MK-3475-158/KEYNOTE-158)帕博利珠单抗 (MK-3475). 在不久的将来,如果试验显示出积极的结果,那么它将推动市场,因为未来几年内有望出现子宫内膜癌的新疗法。

因此,由于上述因素,预计市场在不久的将来会出现增长。

MEA key trend 1.png

竞争格局

中东和非洲子宫癌治疗和诊断市场具有综合竞争力,大多数处理该市场的公司都是全球参与者。然而,随着技术的不断进步,小公司也开始关注市场渗透,并努力抢占足够的市场份额。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Awareness About Uterine Diseases and Their Available Therapies

      2. 4.2.2 Increasing Health Care Expenditure in Drug Development and Subsequent Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs

      2. 4.3.2 High Cost Associated With the Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Endometrial Adenocarcinoma

      2. 5.1.2 Adenosquamous Carcinoma

      3. 5.1.3 Papillary Serous Carcinoma

      4. 5.1.4 Uterine Sarcoma

    2. 5.2 By Product

      1. 5.2.1 Therapeutics

        1. 5.2.1.1 Surgery

        2. 5.2.1.2 Immunotherapy

        3. 5.2.1.3 Radiation Therapy

        4. 5.2.1.4 Chemotherapy

        5. 5.2.1.5 Others Therapeutics

      2. 5.2.2 Diagnostics

        1. 5.2.2.1 Biopsy

        2. 5.2.2.2 Pelvic Ultrasound

        3. 5.2.2.3 Hysteroscopy

        4. 5.2.2.4 Dilation and Curettage

        5. 5.2.2.5 CT Scan

    3. 5.3 Geography

      1. 5.3.1 Middle-East & Africa

        1. 5.3.1.1 GCC

        2. 5.3.1.2 South Africa

        3. 5.3.1.3 Rest of Middle-East & Africa

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Merck & Co., Inc

      3. 6.1.3 Takeda Pharmaceutical Company Limited

      4. 6.1.4 Siemens Healthcare Inc

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 Novartis AG

      7. 6.1.7 Sanofi

      8. 6.1.8 GlaxoSmithKline Plc

      9. 6.1.9 Becton, Dickinson & Company

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The MEA Uterine Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The MEA Uterine Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 5.7% over the next 5 years.

Abbott Laboratories, Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, F. Hoffmann-La Roche Ltd are the major companies operating in MEA Uterine Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!